Corvex Inc Dossier - Source-backed chat

Corvex Inc

MOVENASDAQ

SectorInformation Technology

IndustryInternet Services & Infrastructure

Beta (adjusted)1.17

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $11.44Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $361M

Shares Outstanding 31.6M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Movano Inc. (renamed Corvex, Inc. effective March 23, 2026, trading under the ticker MOVE) has undergone a radical structural transformation. On March 19, 2026, the company completed an all-stock merger with Corvex OpCo, pivoting its core business from wearable medical devices (such as the FDA-cleared EvieMED Ring) to high-performance AI cloud computing and GPU-accelerated infrastructure. While the merger successfully resolved Nasdaq delisting concerns by boosting stockholders' equity to $576.0 million, it introduces massive dilution. Stockholders face a critical vote on June 22, 2026, to approve the conversion of Series C and D preferred shares, which could expand the share count to over 70.6 million pro forma shares. Given the early stage of the AI platform's commercialization and the pending transition of legacy assets, a Hold recommendation is advised until execution stability and top-line run-rates are established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The conversion of Series C and D preferred shares causes severe market indigestion due to the massive influx of pro forma common shares (expanding from ~1.98 million outstanding to over 70.6 million pro forma). High capital expenditures for GPU clusters strain the balance sheet, and interest expenses outpace revenue conversion. Furthermore, failure to monetize legacy healthcare assets leads to cash burn, while intense competition from larger hyperscalers compresses AI cloud margins.

Base CaseCentral scenario

The combined company successfully transitions into a pure-play AI infrastructure provider. Stockholders approve the preferred stock conversion at the June 22, 2026, annual meeting, enabling the full integration of Corvex's GPU-accelerated cloud platform. Legacy healthcare assets are sold or licensed, providing non-dilutive capital to fund high-intensity GPU cluster expansions. Revenue scales in line with pro forma expectations, and the company leverages its verified production deployment of confidential computing on NVIDIA HGX B200 systems to win enterprise and federal contracts.

Bull CaseUpside scenario

AI infrastructure TAM expansion and secular tailwinds, corporate re-rating from the merger/strategy shift, and low reported leverage providing balance sheet optionality.

Scenarios reflect our research view at the research date.

Key Investment Merits

Successful pivot to high-growth AI cloud computing and GPU-accelerated infrastructure, addressing a massive addressable market.
Resolved immediate Nasdaq delisting risks by increasing stockholders' equity to $576.0 million as of March 31, 2026.
Verified production deployment of confidential computing for AI on NVIDIA HGX B200 systems, providing a strong competitive moat for regulated workloads.
Potential non-dilutive funding from the permitted sale or licensing of legacy medical device assets (EvieMED Ring and mmWave RF technology).

Key Investment Risks

Extreme equity dilution, with pro forma shares outstanding potentially expanding to 70.6 million upon stockholder approval of Series C and D preferred conversions.
High capital intensity of the AI infrastructure business model, requiring substantial ongoing CapEx to scale GPU clusters.
Execution and integration risks associated with a complete business model pivot from medical devices to enterprise software and cloud computing.
Customer concentration and intense competition from well-capitalized hyperscale cloud providers.

Thesis Invalidation Triggers

Rejection of the Conversion Proposal or Option Proposal at the virtual Annual Meeting on June 22, 2026.
Failure to secure additional GPU allocations or power capacity to scale the AI Factory.
Rapid cash burn exceeding the $29.3 million cash buffer without corresponding top-line revenue growth.
Inability to find a buyer or licensing partner for the legacy healthcare assets, resulting in continued operational drag.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.